BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 27, 2007
View Archived Issues
AC-220 well tolerated in phase I acute myeloid leukemia study
Read More
Btk inhibition with PCI-32765 evaluated in mouse lymphoma models
Read More
Adjunctive N-acetyl cysteine beneficial in schizophrenia patients
Read More
University of Montana reports new imaging agents for positron emission tomography (PET)
Read More
Advances in HIV treatment disclosed in recent patents
Read More
Researchers find that component in male semen enhances HIV infection
Read More
GSK completes acquisition of Reliant and obtains U.S. and Porto Rican rights to Lovaza
Read More
SK-PC-B70M reverses scopolamine-induced memory deficits in vivo
Read More
Kalypsys initiates phase IIa clinical trial of KD-7040 for postherpetic neuralgia
Read More
Array BioPharma reports results from phase II study of AZD-6244 in advanced melanoma
Read More
Ambrx enters collaboration with Merck & Co. to develop FGF-21 follow-up type 2 diabetes drug
Read More
Recent Dainippon and Roche patents describe new treatment options for cardiovascular diseases
Read More
FDA grants orphan drug status to Anthera's A-001 for acute chest syndrome in sickle cell disease
Read More
BioCancell and VBDC partner to perform clinical trial of BC-819 in pancreatic cancer
Read More
NXL-105 selected for preclinical development
Read More
Otsuka acquires rights to IV Busulfex from PDL BioPharma
Read More
First patient dosed in phase III program for bapineuzumab in Alzheimer's
Read More
E.U. Commission approves first-in-class integrase inhibitor Isentress for HIV therapy
Read More
FDA grants IND authorization to Athersys for phase I clinical trial of MultiStem for AMI
Read More
Elan and Transition Therapeutics initiate dosing in phase II clinical study of ELND-005 for AD
Read More
Amicus reports positive results from four phase II clinical trials of Amigal for Fabry disease
Read More
Human Genome Sciences acquires rights to Aegera's AEG-40826 for cancer
Read More
Bayer discontinues marketing of Viadur; Vantas now only 12-month implant for prostate cancer in U.S.
Read More
ISTA submits NDA to FDA for Xibrom for inflammation, pain and photophobia
Read More
Millennium submits supplemental NDA to FDA for Velcade for multiple myeloma
Read More
FDA accepts and designates for priority review Jerini's NDA for icatibant for HAE
Read More
European Commission grants marketing authorization to Abbott's Humira for psoriasis
Read More